ClinicalTrials.gg
CompletedNCT04345393Updated Oct 20, 2026Results posted

Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes

An interventional study of Digital Transformation Network (DTN) Program in Inflammatory Bowel Disease (IBD), sponsored by Icahn School of Medicine at Mount Sinai. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention

How we know

Updated Oct 20, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
659
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 3 under way, none of them phase 3. Inflammatory Bowel Diseases · Icahn School of Medicine at Mount Sinai.

Started
2022
with 1 other
No phase
5 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 8th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

2 of the 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Inflammatory Bowel Diseases by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potential to bridge this gap, but the question remains as to how to translate it to mainstream practice while providing individualized recommendations to improve population health across organizations. Through the creation of a Digital Transformation Network (DTN) for Inflammatory Bowel Disease (IBD), the study team plans to reduce digital disparities and scientifically test the impact of these technologies in a clinical trial in three CTSA sites catering to diverse populations and communities.

Read the detailed description

Delivery of healthcare has been traditionally limited to in-person office visits or hospitalizations, while patients spent the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes ePRO has the potential to bridge this gap, but it is unclear how to implement in a mainstream clinical practice that can lead to high-level patient and provider adoption. Through the creation of a Digital Transformation Network (DTN) for Inflammatory Bowel Disease (IBD), the study team plans to reduce digital disparities and scientifically address the evidence gap of digital health interventions across populations and communities.

AIM I. Unify existing digital assets (mobile app, ePROs, assessment for digital disparities and behavioral health, referral to IBD home and health education) into an IBD Digital Therapeutics Toolkit and integrate with EHRs at 3 CTSA hubs. Hypothesis: Integration with EHRs will lead to higher adoption by providers and limit disruption of workflow.

AIM II: Establish baseline levels of digital connectivity, disease control, quality of life and care metrics in cohorts at the three IBD centers. Hypothesis: A multipronged approach of assessment through text, phone, an app, and in-person will yield higher adoption.

AIM III. Implement and evaluate precision-matched interventions (digital skills, social determinants, behavioral health, monitoring through apps, and referral to interdisciplinary care) among 1500 patients with IBD using a stepped-wedge, cluster- randomized trial. Hypothesis: Medical homes supported by a unified platform will translate to sustainable improvement in population health outcomes. Analyze the Impact of DTN interventions. The primary outcome will be the improvement of the percentage of patients in DTN in disease control and decrease in urgent care utilization (emergency department visits and hospitalization days) across the three CTSA sites.

AIM IV. Support sustainability and dissemination across CTSA sites. Hypothesis: The patient- centric DTN will be sustainable through alignment with value-based healthcare.

Anticipated Impact: About 2 million Americans suffer from IBD and many more with chronic inflammatory diseases. The study team hopes that this study will help the study team build an evidence-based approach to determine whether digital medicine can engage a diverse group of patients and improve outcomes; and if yes, how it can be reproduced and replicated across different settings to address theT3 and T4 translational gaps.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)

Keywords

  • IBD
  • Treat to target
  • Digital transformation network
  • Social determinants of health
  • e-PRO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed Inflammatory Bowel Disease (IBD) will be enrolled into DTN in stepped-wedge cluster randomized trial
  • Age greater than or equal to 18 years
  • Ability to speak or understand English or Spanish Language.

Exclusion criteria

Exclusion Criteria:

- Condition or disease that, in the opinion of the investigators, may make it exceedingly difficult for the patient to use DTN, including, but not limited to, advanced dementia.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
659 participants (actual)

Study arms

  • Experimental
    Digital Transformation Network (DTN) Program

    IBD patients at the 3 sites will be sent a message to their Smartphone

    Behavioral: Digital Transformation Network (DTN) Program

Interventions

  • BehavioralDigital Transformation Network (DTN) Program

    Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants in Disease Control

    Proportion of participants in disease control at assessments at end of control period (week 0) and at end of intervention period (week 52). Disease control is defined by normalization of inflammatory markers and ePROs (PRO2\<8 and PRO3\<13). PRO2 measures stool frequency and bleeding while PRO3 measures the number of liquid or soft stools, abdominal pain and general well-being. Inflammatory markers including Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Fecal Calprotectin will be dichotomized using cut-offs of \<30mm/hr, \<5mg/L and \<250 μg/g respectively for normal values.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  2. Change in Number of Unplanned Acute Care

    Change in number of unplanned acute care. Unplanned acute care is defined as the number of ED visits and hospitalizations days 12 months before the intervention and the last 12 months of DTN intervention.

    Time frame: 12 months before intervention and 12 months after intervention

Secondary outcomes

  1. Northstar Digital Literacy Assessment

    For participants who screened positive for needing assistance with digital connectivity and skills. Digital skills and connectivity will be assessed using the Northstar digital literacy assessment. A 17-item rating scale, with full score from 0 to 100, with score 85% or above achieve a passing score.

    Time frame: week 52

  2. Digital Disparities Module

    For participants who screened positive for needing assistance with digital connectivity and skills. The digital disparities module is still in development through SBIR. The digital disparities module will assess the impact of digital disparities module in improving digital skills and access to Internet using previously developed digital disparities assessment instrument. The scale for the digital disparities assessment full scale from 0 - 100 where a higher score indicates the patient has a higher level of disparity in digital connectivity, digital skills and digital usage.

    Time frame: 1 year after enrollment

  3. Change in Overall Health Numeric Rating Scale [OHNRS]

    OHNRS - Full scale from 0 to 10, higher score indicates better health outcomes

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  4. Change in PROMIS Global Scales

    Change in PROMIS Global scales is a 14-item measure that is part of the PROMIS Social Function. The measure refers to social roles, such as work and family responsibilities, and more discretionary social activities, such as leisure activity and relationships with friends. standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  5. Change in Patient Health Questionnaire (PHQ-4)

    The Patient Health Questionnaire (PHQ)-4 s a 4 item inventory. Anxiety subscale from 0-6, depression subscale from 0-6, with full scale from 0-12, higher score indicates more symptoms.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  6. Change in Patient Health Questionnaire (PHQ-8)

    The Questionnaire Type 9 for Depression (PHQ-8) is a self-administered instrument. Full scale from 0-24, with higher score indicating more severe symptoms. As needed.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  7. Change in Generalized Anxiety Disorder Scale (GAD-7)

    The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire. Full scale from 0-21, with higher score indicating more symptoms. As needed.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  8. Improvement in Mucosal Healing

    Improvement in mucosal healing will be defined as the absence of inflammation on endoscopy (scoring systems) or imaging notes collected from EHR.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  9. Proportion of Participants With Medication Adherence

    Proportion of participants with medication adherence will be assessed with the Visual Analog Scale (VAS) using \<80% cut-off to designate non-adherence. Full Scale from 0 to 100 with higher score indicating more adherence.

    Time frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)

  10. System Usability Scale (SUS)

    The system usability scale (SUS) is a 10-item Likert scale questionnaire. The range of scores is from 0 - 100 where a SUS score above 68 is considered average.

    Time frame: End of Intervention Period (Week 52)

  11. Net Promoter Score

    The Net Promoter is a 10 point scale and the full score ranges from -100 to 100 where a higher score translates to higher satisfaction with a product.

    Time frame: End of Intervention Period (Week 52)

07

Results

Posted Oct 20, 2026

Participant flow

Enrollment began May 2022 at IBD Centers at Icahn School of Medicine at Mount Sinai, Cleveland Clinic and UC Davis. Due to significant delays, enrollment at all sites enrolled as soon as possible at the same time and a cluster randomized study with a stepped wedge study design was not utilized.

Control Period (up to 22 Months)
Participant flow — Control Period (up to 22 Months)
MilestoneIcahn School of Medicine at Mount SinaiCleveland ClinicUC Davis
Started395145119
Completed382135106
Not completed131013
Withdrew: Withdrawal by subject131013
DTN Intervention (52 Weeks)
Participant flow — DTN Intervention (52 Weeks)
MilestoneIcahn School of Medicine at Mount SinaiCleveland ClinicUC Davis
Started382135106
Completed2389875
Not completed1443731
Withdrew: Withdrawal by subject922523
Withdrew: Lost to follow-up52128

Outcome measures

PrimaryProportion of Participants in Disease Control

Proportion of participants in disease control at assessments at end of control period (week 0) and at end of intervention period (week 52). Disease control is defined by normalization of inflammatory markers and ePROs (PRO2\<8 and PRO3\<13). PRO2 measures stool frequency and bleeding while PRO3 measures the number of liquid or soft stools, abdominal pain and general well-being. Inflammatory markers including Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Fecal Calprotectin will be dichotomized using cut-offs of \<30mm/hr, \<5mg/L and \<250 μg/g respectively for normal values.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Number · proportion of participants
Proportion of Participants in Disease Control
proportion of participantsDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—0.43 ± 0.03
End of Intervention Period (Week 52)0.55 ± 0.02—
PrimaryChange in Number of Unplanned Acute Care

Change in number of unplanned acute care. Unplanned acute care is defined as the number of ED visits and hospitalizations days 12 months before the intervention and the last 12 months of DTN intervention.

Time frame:
12 months before intervention and 12 months after intervention
Reported as:
Mean · events
Change in Number of Unplanned Acute Care
eventsDigital Transformation Network (DTN) ProgramControl Arm
12 months before intervention—3.66 ± 9.50
12 months after intervention1.41 ± 4.33—
SecondaryNorthstar Digital Literacy Assessment

For participants who screened positive for needing assistance with digital connectivity and skills. Digital skills and connectivity will be assessed using the Northstar digital literacy assessment. A 17-item rating scale, with full score from 0 to 100, with score 85% or above achieve a passing score.

Time frame:
week 52

No measurements were reported for this outcome.

SecondaryDigital Disparities Module

For participants who screened positive for needing assistance with digital connectivity and skills. The digital disparities module is still in development through SBIR. The digital disparities module will assess the impact of digital disparities module in improving digital skills and access to Internet using previously developed digital disparities assessment instrument. The scale for the digital disparities assessment full scale from 0 - 100 where a higher score indicates the patient has a higher level of disparity in digital connectivity, digital skills and digital usage.

Time frame:
1 year after enrollment

No measurements were reported for this outcome.

SecondaryChange in Overall Health Numeric Rating Scale [OHNRS]

OHNRS - Full scale from 0 to 10, higher score indicates better health outcomes

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Mean · score on a scale
Change in Overall Health Numeric Rating Scale [OHNRS]
score on a scaleDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—6.08 ± 1.80
End of Intervention Period (Week 52)6.99 ± 1.81—
SecondaryChange in PROMIS Global Scales

Change in PROMIS Global scales is a 14-item measure that is part of the PROMIS Social Function. The measure refers to social roles, such as work and family responsibilities, and more discretionary social activities, such as leisure activity and relationships with friends. standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Mean · T score
Change in PROMIS Global Scales
T scoreDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—45.63 ± 9.13
End of Intervention Period (Week 52)46.30 ± 8.30—
SecondaryChange in Patient Health Questionnaire (PHQ-4)

The Patient Health Questionnaire (PHQ)-4 s a 4 item inventory. Anxiety subscale from 0-6, depression subscale from 0-6, with full scale from 0-12, higher score indicates more symptoms.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Mean · score on a scale
Change in Patient Health Questionnaire (PHQ-4)
score on a scaleDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—3.51 ± 3.08
End of Intervention Period (Week 52)1.47 ± 1.80—
SecondaryChange in Patient Health Questionnaire (PHQ-8)

The Questionnaire Type 9 for Depression (PHQ-8) is a self-administered instrument. Full scale from 0-24, with higher score indicating more severe symptoms. As needed.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Mean · score on a scale
Change in Patient Health Questionnaire (PHQ-8)
score on a scaleDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—13.12 ± 9.03
End of Intervention Period (Week 52)2.90 ± .04—
SecondaryChange in Generalized Anxiety Disorder Scale (GAD-7)

The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire. Full scale from 0-21, with higher score indicating more symptoms. As needed.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Mean · score on a scale
Change in Generalized Anxiety Disorder Scale (GAD-7)
score on a scaleDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—7.01 ± 5.16
End of Intervention Period (Week 52)2.35 ± 2.91—
SecondaryImprovement in Mucosal Healing

Improvement in mucosal healing will be defined as the absence of inflammation on endoscopy (scoring systems) or imaging notes collected from EHR.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)

No measurements were reported for this outcome.

SecondaryProportion of Participants With Medication Adherence

Proportion of participants with medication adherence will be assessed with the Visual Analog Scale (VAS) using \<80% cut-off to designate non-adherence. Full Scale from 0 to 100 with higher score indicating more adherence.

Time frame:
End of Control Period (Week 0) and End of Intervention Period (Week 52)
Reported as:
Number · proportion of participants
Proportion of Participants With Medication Adherence
proportion of participantsDigital Transformation Network (DTN) ProgramControl Arm
End of Control Period (Week 0)—0.91 ± 0.01
End of Intervention Period (Week 52)0.93 ± 0.01—
SecondarySystem Usability Scale (SUS)

The system usability scale (SUS) is a 10-item Likert scale questionnaire. The range of scores is from 0 - 100 where a SUS score above 68 is considered average.

Time frame:
End of Intervention Period (Week 52)
Reported as:
Mean · score on a scale
System Usability Scale (SUS)
score on a scaleDigital Transformation Network (DTN) Program
System Usability Scale (SUS)37.56 ± 14.51
SecondaryNet Promoter Score

The Net Promoter is a 10 point scale and the full score ranges from -100 to 100 where a higher score translates to higher satisfaction with a product.

Time frame:
End of Intervention Period (Week 52)
Reported as:
Mean · score on a scale
Net Promoter Score
score on a scaleDigital Transformation Network (DTN) Program
Net Promoter Score7.63 ± 2.56

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Digital Transformation Network (DTN) Program0/659 (0%)0/659 (0%)0/659 (0%)
Control Arm0/659 (0%)0/659 (0%)0/659 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Mean41.27 ± 15.5444.78 ± 13.9946.72 ± 16.7043.02 ± 15.57
Sex: Female, Male
Sex: Female, Male(Participants)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Female23610768411
Male1593851248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Hispanic or Latino05914
Not Hispanic or Latino1713391241
Unknown or Not Reported378719404
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Amerian Indian or Alaska Native0101
Asian182424
Native Hawaiian or Other Pacific Islander0000
Black or African American2310437
White27512594494
More than one race3104
Other580563
Unknown or Not Reported1861236
ED visits
ED visits(ED visits)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Mean0.70 ± 1.631.36 ± 3.090.96 ± 2.020.89 ± 2.11
Hospital stays
Hospital stays(days)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Mean2.63 ± 8.113.60 ± 10.632.24 ± 5.732.77 ± 8.35
OHNRS
OHNRS(score on a scale)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Mean6.24 ± 1.715.80 ± 1.775.95 ± 2.056.08 ± 1.80
PROMIS
PROMIS(score on a scale)Icahn School of Medicine at Mount SinaiCleveland CliniciUC DavisTotal
Mean32.83 ± 7.1631.26 ± 7.0431.33 ± 8.5132.18 ± 7.44

2 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • University of California, Davis
    Davis, California 95616, United States
  • RxHealth
    Secaucus, New Jersey 07094, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195-0001, United States
09

References and documents

Publications

  • Tiles-Sar N, Neuser J, de Sordi D, Baltes A, Preiss JC, Moser G, Timmer A. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2025 Apr 17;4(4):CD006913. doi: 10.1002/14651858.CD006913.pub3. PubMed 40243391 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Mar 2025, 34 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 34 months is above that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Apr 14, 2020
StartActual
May 14, 2022
Primary completionActual
Mar 24, 2025
CompletionActual
Mar 24, 2025
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Enrollment
543→659
Oct 20, 2026
Interventions
Arms removed: Control Arm
Oct 20, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedNumberProportion of Participants in Disease ControlTime frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • Time frameChange in Number of Unplanned Acute Carebaseline → 12 months before intervention and 12 months after intervention
  • DescriptionChange in Number of Unplanned Acute Care: how it is measured was reworded
Oct 20, 2026
Secondary outcomes
6 edited, 3 time frame changed, 1 added, 2 removed, 2 description edited
What changed in the outcomes
  • EditedChange in Overall Health Numeric Rating Scale [OHNRS]Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • EditedChange in PROMIS Global scalesScalesTime frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • EditedChange in Patient Health Questionnaire (PHQ-4)Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • EditedChange in Patient Health Questionnaire (PHQ-98)Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • EditedChange in Generalized Anxiety Disorder scaleScale (GAD-7)Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • EditedNumber of participants with improvementImprovement in mucosal healingMucosal HealingTime frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • AddedProportion of Participants With Medication AdherenceTime frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
  • RemovedVisual Analog Scale (VAS)Time frame: 1 year after enrollment
  • RemovedProportion of patients meeting eligible quality metricsTime frame: 1 year after enrollment
  • Time frameNorthstar Digital Literacy Assessment1 year after enrollment → week 52
  • Time frameSystem Usability Scale (SUS)1 year after enrollment → End of Intervention Period (Week 52)
  • Time frameNet Promoter Score1 year after enrollment → End of Intervention Period (Week 52)
  • DescriptionDigital Disparities Module: how it is measured was reworded
  • DescriptionNorthstar Digital Literacy Assessment: how it is measured was reworded
Oct 20, 2026
Sponsor
Collaborators added: National Center for Advancing Translational Sciences (NCATS)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Enrollment 543→659
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedNumberProportion of Participants in Disease ControlTime frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • Time frameChange in Number of Unplanned Acute Carebaseline → 12 months before intervention and 12 months after intervention
    • DescriptionChange in Number of Unplanned Acute Care: how it is measured was reworded
    Secondary outcomes 6 edited, 3 time frame changed, 1 added, 2 removed, 2 description edited
    What changed in the outcomes
    • EditedChange in Overall Health Numeric Rating Scale [OHNRS]Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • EditedChange in PROMIS Global scalesScalesTime frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • EditedChange in Patient Health Questionnaire (PHQ-4)Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • EditedChange in Patient Health Questionnaire (PHQ-98)Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • EditedChange in Generalized Anxiety Disorder scaleScale (GAD-7)Time frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • EditedNumber of participants with improvementImprovement in mucosal healingMucosal HealingTime frame: 1 year after enrollment → End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • AddedProportion of Participants With Medication AdherenceTime frame: End of Control Period (Week 0) and End of Intervention Period (Week 52)
    • RemovedVisual Analog Scale (VAS)Time frame: 1 year after enrollment
    • RemovedProportion of patients meeting eligible quality metricsTime frame: 1 year after enrollment
    • Time frameNorthstar Digital Literacy Assessment1 year after enrollment → week 52
    • Time frameSystem Usability Scale (SUS)1 year after enrollment → End of Intervention Period (Week 52)
    • Time frameNet Promoter Score1 year after enrollment → End of Intervention Period (Week 52)
    • DescriptionDigital Disparities Module: how it is measured was reworded
    • DescriptionNorthstar Digital Literacy Assessment: how it is measured was reworded
    Interventions Arms removed: Control Arm
    Sponsor Collaborators added: National Center for Advancing Translational Sciences (NCATS)
    + 4 other changes: index terms, identifiers, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04345393
Responsible party
Bruce E. Sands (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Apr 14, 2020
Start date
May 14, 2022
Primary completion
Mar 24, 2025
Completion
Mar 24, 2025
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Bruce Sands, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion